Dyne Therapeutics, Inc. 4

CFO Erick Lucera executed an automatic tax-withholding sale of 1,797 shares of Dyne Therapeutics common stock on 2026-08-13 for roughly $47K under a 10b5-1 plan tied to RSU vesting.

On August 13, 2026, Dyne Therapeutics, Inc. Chief Financial Officer Erick Lucera automatically sold 1,797 shares of common stock at a weighted average price of approximately $26.28 per share, for total proceeds of about $47,200, solely to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units under a pre-arranged Rule 10b5-1-compliant agreement; following this tax-related sale, he reported direct ownership of 119,766 shares of common stock, including 106,451 unvested RSUs, indicating the transaction was non-discretionary and compensation-related rather than a voluntary reduction in his economic exposure to the company.

Filing Facts

CIK

1818794

Ticker

DYN

Form

4

Source Type

fda

Accession

0001697616-26-000002

Alert Tier

5